AshiBio
Burlingame, US · 3 known investors
āshibio is a clinical-stage biotech developing therapies for bone and connective tissue disorders, with clinical programs targeting heterotopic ossification conditions (including fibrodysplasia ossificans progressiva) and autosomal dominant osteopetrosis type 2. Its pipeline includes andecaliximab and vantictumab, aimed at preventing symptom onset or slowing disease progression for affected patients.